Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

Manage portfolio risks
Analyze success factors
Create meaningful benchmarks

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

Cutting edge thought leadership
Expert analysis
Hear from news makers

Datamonitor Healthcare

Datamonitor Healthcare's Top Research Reports

21 Jan 2020

View white paper
In Vivo

Outlook 2020 Report

18 Dec 2019

Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.

Single report
In Vivo

Medtechs Enter The Decade of Digital, Consumers and Wellness

By Ashley Yeo 11 Dec 2019

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

View analysis
In Vivo

Critical Insights into Market Access

10 Dec 2019

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

View infographic
In Vivo

Brexit To And Fro Continues Into Fresh Decade

By Ian Schofield 06 Dec 2019

Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

Topic Business Strategies Policy and regulation

View analysis
In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 28 Nov 2019

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

View analysis
In Vivo

MHealth And Research In Oncology

By Niharika Dandamudi 20 Nov 2019

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”

Topic Digital Health Personalized Medicine

View analysis
In Vivo

How Proximity Creates Partnerships

By William Looney 08 Nov 2019

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Topic Business strategies Deal trends

View article
Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

Topic Cell and gene therapy Drug development landscape Drug approval

Full video
In Vivo

GSK's Hal Barron On R&D Progress At Two-Year Mark

By Andrew McConaghie 01 Nov 2019

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

Topic Business strategies Drug development landscape Research

View article
Awareness, Datamonitor Healthcare

Post-ESMO Podcast 2019

31 Oct 2019

Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.

Topic Cancer Research

Full podcast
Biomedtracker, Datamonitor Healthcare

2019 Post-ESMO Conference Report Extract

31 Oct 2019

Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.

Topic Cancer Drug development landscape Research

Single report
Datamonitor Healthcare

Insight into NASH Pricing Strategies

By Hannah Cohen 25 Oct 2019

Explore the key hurdles to anticipating the initial and potential value of the NASH therapy market.

Topic Drug approval Business strategies

View white paper
Datamonitor Healthcare

Providing Coverage of the Commercial Topics in Q3

10 Oct 2019

The Commercial Solutions Strategy Suite from Informa Pharma Intelligence unites the power of vital tools to bring you actionable data, penetrating analysis, and a crucial industry view covering a variety of critical market aspects, allowing you to accurately Forecast, Analyze and Benchmark, and Understand the mark landscape.

Topic Drug approval Drug development landscape

View article
Biomedtracker, Datamonitor Healthcare

Key potential drug launches 2020

27 Sep 2019

Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

Topic Drug approval Drug review Drug development landscape

View infographic